Evidence map›Paper›PMID 37190112›Full record

ArticleCells2023

Overexpression of GREM1 Improves the Survival Capacity of Aged Cardiac Mesenchymal Progenitor Cells via Upregulation of the ERK/NRF2-Associated Antioxidant Signal Pathway.

Gurleen Kaur, Xiaoliang Wang, Xiuchun Li, Hannah Ong, Xiangfei He, Chuanxi Cai

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gurleen KaurDepartment of Molecular and Cellular Physiology, Department of Medicine, Albany Medical College, Albany, NY 12208, USA.
Xiaoliang WangDepartment of Molecular and Cellular Physiology, Department of Medicine, Albany Medical College, Albany, NY 12208, USA.
Xiuchun LiDepartment of Molecular and Cellular Physiology, Department of Medicine, Albany Medical College, Albany, NY 12208, USA.ORCID 0000-0002-5604-9538
Hannah OngDepartment of Surgery, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.ORCID 0000-0002-6041-0322
Xiangfei HeDepartment of Surgery, Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
Chuanxi CaiDepartment of Molecular and Cellular Physiology, Department of Medicine, Albany Medical College, Albany, NY 12208, USA.
The Ohio State University Wexner Medical Center · USBrigham and Women's Hospital · US

Funding

Enhancing the effectiveness of human cardiac stem cell therapyR01HL114951 · NHLBI · UNIVERSITY OF LOUISVILLE · PI CAI, CHUANXI · 2012 to 2016
$1.9M
NHLBI NIH HHS R01 HL114951NIH HHS R01HL114951
6 · The paper itself

Abstract

Ischemic heart disease is the leading cause of mortality in the United States. Progenitor cell therapy can restore myocardial structure and function. However, its efficacy is severely limited by cell aging and senescence. Gremlin-1 (GREM1), a member of the bone morphogenetic protein antagonist family, has been implicated in cell proliferation and survival. However, GREM1's role in cell aging and senescence has never been investigated in human cardiac mesenchymal progenitor cells (hMPCs). Therefore, this study assessed the hypothesis that overexpression of GREM1 rejuvenates the cardiac regenerative potential of aging hMPCs to a youthful stage and therefore allows better capacity for myocardial repair. We recently reported that a subpopulation of hMPCs with low mitochondrial membrane potential can be sorted from right atrial appendage-derived cells in patients with cardiomyopathy and exhibit cardiac reparative capacity in a mouse model of myocardial infarction. In this study, lentiviral particles were used to overexpress GREM1 in these hMPCs. Protein and mRNA expression were assessed through Western blot and RT-qPCR. FACS analysis for Annexin V/PI staining and lactate dehydrogenase assay were used to assess cell survival. It was observed that cell aging and cell senescence led to a decrease in GREM1 expression. In addition, overexpression of GREM1 led to a decrease in expression of senescence genes. Overexpression of GREM1 led to no significant change in cell proliferation. However, GREM1 appeared to have an anti-apoptotic effect, with an increase in survival and decrease in cytotoxicity evident in GREM1-overexpressing hMPCs. Overexpressing GREM1 also induced cytoprotective properties by decreasing reactive oxidative species and mitochondrial membrane potential. This result was associated with increased expression of antioxidant proteins, such as SOD1 and catalase, and activation of the ERK/NRF2 survival signal pathway. Inhibition of ERK led to a decrease in GREM1-mediated rejuvenation in terms of cell survival, which suggests that an ERK-dependent pathway may be involved. Taken altogether, these results indicate that overexpression of GREM1 can allow aging hMPCs to adopt a more robust phenotype with improved survival capacity, which is associated with an activated ERK/NRF2 antioxidant signal pathway.

Indexed as

AntioxidantsMesenchymal Stem CellsAgedAnimalsBone Morphogenetic ProteinsCytokinesHumansIntercellular Signaling Peptides and ProteinsMiceNF-E2-Related Factor 2Signal TransductionUp-RegulationAntioxidantsBone Morphogenetic ProteinsCytokinesGREM1 protein, humanGrem1 protein, mouseIntercellular Signaling Peptides and ProteinsNF-E2-Related Factor 2antioxidantcell survivalGREM1human cardiac mesenchymal progenitor cells (hMPCs)oxidative stresssenescence

Identifiers

PMID37190112
PMCPMC10136744
OpenAlexW4366775027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.